Corcept Therapeutics Executive Compensation Revealed
Ticker: CORT · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1088856
Sentiment: neutral
Topics: executive-compensation, proxy-statement, stock-options
TL;DR
Corcept exec comp details out, stock options for Belanoff, Guyer, Maduck, Mokari, Robb.
AI Summary
Corcept Therapeutics Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock options granted to key executives such as Joseph K. Belanoff, M.D., William Guyer, Pharm.D., Sean Maduck, Atabak Mokari, and Charles Robb.
Why It Matters
This filing provides transparency into how Corcept Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present immediate financial risks.
Key Players & Entities
- Corcept Therapeutics Inc. (company) — Filer of the DEF 14A
- Joseph K. Belanoff, M.D. (person) — Executive who received stock options
- William Guyer, Pharm.D. (person) — Executive who received stock options
- Sean Maduck (person) — Executive who received stock options
- Atabak Mokari (person) — Executive who received stock options
- Charles Robb (person) — Executive who received stock options
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
For which fiscal year does this filing primarily report compensation data?
This filing primarily reports compensation data for the fiscal year ending December 31, 2024.
Which key executives are mentioned in relation to stock option grants?
Joseph K. Belanoff, M.D., William Guyer, Pharm.D., Sean Maduck, Atabak Mokari, and Charles Robb are mentioned in relation to stock option grants.
What is Corcept Therapeutics Inc.'s Standard Industrial Classification (SIC) code?
Corcept Therapeutics Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Joseph K. Belanoff, M.D. regarding CORCEPT THERAPEUTICS INC (CORT).